Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 010DS-Zn
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages
Details : Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells.
Product Name : 010DS-Zn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : 010DS-Zn
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable